australian healthcare

Latest news and analysis on australian healthcare

Buy Hold Sell

Buy Hold Sell: 5 ASX healthcare names to fix what ails you

ASX healthcare’s been flatlining, could a recovery be on the cards? Two top investors name the stocks they think could revive the sector.
ANN
CSL
RMD
+2
Buy Hold Sell
Livewire Markets
Fund in Focus

Investing at the inflexion point in healthcare innovation

Deep expertise, high conviction investing, in some of the most exciting and innovative healthcare companies in the world.
SNT
Chris Conway
Livewire Markets
Growth

Punching above our weight: backing world-class Aussie biotechs

Specialist expertise, months of due dilligence, and high conviction investments - KP Rx's formula for healthcare growth investing.
Chris Conway
Livewire Markets
Equities

Morgan Stanley’s top-ranked ASX healthcare picks for right now

With the ability to offset the impact of tariffs and strong historical performance in tough times, the health sector could be one to watch.
CSL
RMD
Tom Stelzer
Livewire Markets
Reporting Season

After a 200% rise in a year, does Pro Medicus have another gear?

We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.
Chris Conway
Livewire Markets
Reporting Season

3 ASX growth stocks to watch as earnings hit a turning point

Earnings may have bottomed out and there's hope in the air this reporting season, according to FNArena's Rudi Filapek-Vandyck
COH
+8
Sara Allen
Livewire Markets
Equities

The ASX-listed Biotech set to unlock significant value

This $60m ASX-listed biotech, with a cutting-edge pipeline of transformative therapies, stands at a key inflection point for value creation.
CSL
PXS
+1
Hashan De Silva
KP Rx
Equities

What it will take to create the next CSL or Telix Pharmaceuticals

The Aussie biotech space is small but mighty – what will it take to see it surge?
Sara Allen
Livewire Markets
Equities

Where to find value opportunities in Australian healthcare and 3 stocks to watch

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.
CSL
+5
Sara Allen
Livewire Markets
Reporting Season

The healthcare unicorn that is back on track and posting strong numbers

It's been a wild ride for ResMed over the past couple of years and while there might be further volatility, things are back on track
RMD
Chris Conway
Livewire Markets
Fund in Focus
Sponsored

Why Elanor is doubling down in healthcare real estate

The first fund was a hit with investors. Now, Elanor Investors Group are launching a second healthcare real estate fund.
Hans Lee
Livewire Markets
The Pitch

How specialisation is driving growth for this healthcare property fund

Many businesses are focusing on specialisation, to set themselves apart from their competitors - Real Asset Management is no different
Chris Conway
Livewire Markets
The Pitch

How big data powers healthcare decisions (and how you can invest in the opportunity)

We know that big data is impacting just about everything, so it should come as no surprise that it influences where hospitals are built
Chris Conway
Livewire Markets
The Pitch

The Aussie healthcare opportunity hiding in plain sight

Australian investors are savvy when it comes to opportunities in healthcare - but this one has flown under the radar (until now).
Chris Conway
Livewire Markets
Equities

This small-cap healthcare stock has significant AI tailwinds

How Integral Diagnostics is harnessing AI and teleradiology to scale operations and capitalise on a fragmented imaging market.
Eleanor Swanson
Firetrail Investments
Undiscovered Funds

This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it
AVH
Chris Conway
Livewire Markets
Undiscovered Funds

Backed by industry titans, this fundie is leveraging Australia's healthcare innovation

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.
Chris Conway
Livewire Markets
Equities

Hidden growth potential in this ASX microcap

We believe lacklustre revenue growth and lumpy profitability mask the potential of SDI Limited’s post-COVID strategic shift
Luke Winchester
Merewether Capital
Equities

Neuren – Where to from here?

There is much more to come from Neuren. Following two years of substantial progress, we see significant upside from current levels.
+1
Hashan De Silva
KP Rx
Reporting Season

Why relentless innovation is Pro Medicus’ biggest opportunity and risk

There are only two states in software according to Pro Medicus CEO Dr Sam Hupert: "quick or dead". And Hupert doesn't much care to be dead.
PME
Chris Conway
Livewire Markets
1-20 of 74